Develops oral small molecule drugs for endocrinology, immunology, and metabolic diseases.
Jun 2026Revenue $98.9M/yrExpenses $142M/yr
Fell below break-even Jan 2024
Figures by year
When will Septerna be profitable again?
Its expenses passed its revenue in Jan 2024. In the 12 months to Jun 2026, revenue was $98.9M and expenses $142M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $46.0M | $114M | −$68.3M |
| Dec 2024 | $1.07M | $81.9M | −$80.8M |
| Dec 2023 | $151K | −$1.92M | $2.08M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.